Table 1.
Characteristics of the study population of Sodium glucose co-transporter 2 inhibitor users and non-users.
| Basic statistic | SGLT2i vs. non-users | SGLT2i vs. non-users | ||||
|---|---|---|---|---|---|---|
| SGLT2i | Diff (1st-last) | Matched non-users | Diff (1st-last) | p-value | p-value Diff (1st-last) | |
| No. | 7,624 | 7,624 | ||||
| Age, year | 61.9 ± 11.6 | 61.5 ± 13. | 0.061 | |||
| Sex (female), % | 41.9% | 42.2% | 0.768 | |||
| Cre (first before drug) (mg/dL) | 0.895 ± 0.354 | −0.035 | 0.889 ± 0.382 | −0.054 | 0.361 | <0.001* |
| Cre (last) (mg/dL) | 0.930 ± 0.432 | 0.943 ± 0.502 | 0.096 | |||
| eGFR (first before drug) (mL/min/1.73 m2) | 92.692 ± 31.425 | 2.554 | 96.798 ± 38.059 | 4.898 | <0.001* | <0.001* |
| eGFR (last) (mL/min/1.73 m2) | 90.138 ± 32.636 | 91.900 ± 35.889 | 0.002 | |||
| HbA1c (first before drug) (%, mmol/mol) | 8.890 ± 1.620 (73.839 ± 17.704) | 0.706 (7.718) | 8.985 ± 2.266 (74.690 ± 24.771) | 0.991 (10.829) | 0.015 (<0.015*) | <0.001* |
| HbA1c (last) (%, mmol/mol) | 8.201 ± 1.407 (66.121 ± 15.376) | 7.994 ± 1.729 (63.861 ± 18.905) | <0.001* | |||
| UACR (first before drug) (mg/g) | 45.445 ± 75.175 | −7.778 | 107.529 ± 542.564 | −0.868 | 0.336 | 0.391 |
| UACR (last) (mg/g) | 53.223 ± 95.205 | 108.397 ± 542.692 | 0.399 |
Age, Cre, eGFR, HbA1c, and UACR presented as mean ± SD.
SGLT-2i, Sodium-glucose co-transporter 2 inhibitor; Diff, difference; Cre, creatinine; eGFR, estimated Glomerular filtration rate; HbA1c, Glycated hemoglobin; UACR, urine albumin to creatinine ratio.
*
p < 0.05.